H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $42

Futu NewsJan 21 19:31 · Ratings

Promising Long-Term Benefits and Market Potential of Blarcamesine in Alzheimer's Treatment Justify Buy Rating for Anavex Life Sciences

TipRanksJan 21 19:18 · Ratings

Anavex Life Sciences Shares Rise After Positive Trial Results for Alzheimer's Treatment

WSJJan 16 02:50

Express News | Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase Iib/III Data in the Journal of Prevention of Alzheimer’s Disease

BreakingsJan 15 20:30

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

GlobeNewswireJan 15 20:30

Anavex Reports Long-Term Benefits of Blarcamesine in Slowing Early Alzheimer's Disease Progression

BenzingaJan 13 21:36